FDA Grants R3 Vascular IDE Approval for ELITE-BTK Pivotal Trial of its MAGNITUDE® Drug Eluting Next Generation Bioresorbable Scaffold for Below-the-Knee Peripheral Arterial Disease
04 nov. 2024 06h00 HE
|
R3 Vascular
MOUNTAIN VIEW, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- R3 Vascular Inc., a medical device company dedicated to developing and providing novel, best-in-class bioresorbable scaffolds for treating...
Sonablate announces first patient enrolled in HIFIVE U.S. clinical trial for ablation of incompetent veins
28 oct. 2024 14h36 HE
|
Sonablate
HIFIVE is a Phase I trial to assess the safety and performance of Sonablate high-intensity focused ultrasound for treating incompetent veins
[Latest] Global Medical Aesthetics Market Size/Share Worth USD 36,168.8 Million by 2033 at a 8.4% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
06 août 2024 03h30 HE
|
Custom Market Insights
Austin, TX, USA, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Medical Aesthetics Market Size, Trends and Insights By Product Type (Aesthetic...
R3 Vascular Appoints Josh Smale as its Vice President of Global Clinical and Scientific Affairs
09 juil. 2024 14h25 HE
|
R3 Vascular
R3 Vascular Inc. is pleased to announce the appointment of Josh Smale as its Vice President of Global Clinical and Scientific Affairs.
R3 Vascular Announces $87 Million in Series B Financing and Appoints Christopher M. Owens as new President and CEO
09 mai 2024 12h00 HE
|
R3 Vascular
R3 Vascular, Inc. announced the closing of its $87 million Series B financing round and the appointment of a new President and Chief Executive Officer
Teleflex Expands Intraosseous Vascular Access Portfolio with New Arrow™ EZ-IO™ Intraosseous Access Procedure Tray
09 mai 2024 06h30 HE
|
Teleflex Incorporated
WAYNE, Pa., May 09, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a global leader in medical technologies and pioneer in intraosseous vascular access, today announced the launch of the...
Therini Bio Announces Positive Preclinical Data Supporting the Development of THN391 in Neurodegenerative Ocular Diseases
08 mai 2024 09h00 HE
|
Therini Bio, Inc.
THN391, a mAb designed to block neuroinflammation triggered by fibrin, demonstrated effectiveness in protecting against vascular and neuronal degeneration
“I Need to See It With My Own Eyes”: How US Ophthalmologists React to Apellis’ Syfovre Safety Warnings When Managing Geographic Atrophy
14 déc. 2023 12h58 HE
|
Spherix Global Insights
Exton, PA, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Geographic Atrophy (GA), the most severe stage of dry age-related macular degeneration (dAMD), poses a significant challenge as retinal cells atrophy,...
Teleflex Awarded Peripheral Access Agreement with Premier, Inc.
05 déc. 2023 06h30 HE
|
Teleflex Incorporated
WAYNE, Pa., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced it was awarded the Peripheral Access purchasing...
Teleflex Announces First Patient Enrollment in ACCESS-MANTA™ Registry
16 nov. 2023 06h30 HE
|
Teleflex Incorporated
WAYNE, Pa., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the first patient enrollment in a clinical...